Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hI-con1 in CNV secondary to AMD
NCT02358889Phase 2Completed
- Sponsor
- Iconic Therapeutics, Inc.
- Start
- Feb 2015
- Primary completion
- Sep 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of hI-con1 in choroidal neovascularization (CNV), sponsored by Iconic Therapeutics, Inc.. Started Feb 2015; status: completed.
02
Drugs
hI-con1
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT02358889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02358889.